AVITA Medical to launch RECELL GO system in US burn centres following FDA approval
Wound care management specialist AVITA Medical (ASX: AVH) has obtained US Food and Drug Administration (FDA) approval for its RECELL GO skin restoration system.
RECELL GO is a cell-harvesting device that utilises the regenerative properties of a patient’s own skin to treat thermal burn wounds and full-thickness skin defects.
Chief executive officer Jim Corbett said RECELL’s use can provide several advantages over traditional skin grafting, including improved healing due to the use of significantly less donor skin.
Transformational treatment
“FDA approval of RECELL GO marks a paradigm shift in the treatment of partial-thickness and full-thickness wounds,” Mr Corbett said.
“By streamlining processes and enhancing operational efficiency with the use of RECELL GO, clinicians can now treat a greater number of patients and more broadly experience the proven benefits of RECELL technology.”
“We believe that this transformative shift will empower more clinicians to achieve optimal outcomes for their patients, driving greater adoption and fundamentally redefining wound care management.”
Mr Corbett said RECELL GO has enhanced features that streamline the preparation of spray-on skin cells, significantly reducing the training burden on medical staff while improving workflow efficiency in the operating room.
Major global market
The World Health Organisation estimates that 11 million burn injuries of all types occur annually worldwide, with the costs of treating these patients varying around the world.
According to SkyQuest Technology, the global burn care market size was valued at $3.6 billion in 2023 and is poised to grow to $6.3b by 2031.
The US burn care market size was valued at around $1.4b in 2022 and is estimated to grow at a compound annual growth rate of 6.33% from 2023 to 2030.
AVITA is planning to launch RECELL GO in top US burn treatment centres in June and other existing accounts will be converted to RECELL GO throughout the year.